

## Retinal Physician Symposium Covers Broad Range of Topics

September 1, 2006

feature

## Retinal Physician Symposium Covers Broad Range of Topics

Top specialists provide insights on timely issues.

**COMPILED BY THE RETINAL PHYSICIAN EDITORIAL STAFF**

Many of the country's leading retina specialists gathered at the Atlantis resort on Paradise Island in the Bahamas from May 31 to June 3 for the Second Annual *Retinal Physician* Symposium (RPS). The theme of this year's meeting was Current Concepts in Retinal Medicine. The meeting generated considerable excitement as Genentech chose the RPS to release the first results of the key PIER trial evaluating quarterly dosing for ranibizumab (Lucentis) in treating wet age-related macular degeneration (AMD).

The following are condensed recaps of key presentations that took place during the 4 days of the Symposium.

### WET AMD TREATMENTS

#### Ranibizumab (Lucentis)

A key focus of this year's RPS was the ongoing assessment of ranibizumab (Lucentis, Genentech). Interest was generated by 2 key events: the release of 1-year data from the PIER trial and the expectation that ranibizumab would be approved by the Food and Drug Administration shortly after the Symposium concluded. Indeed, ranibizumab was approved on June 30 as a treatment for wet AMD.

Peter Kaiser, MD, provided a recap of the key clinical trials for ranibizumab, including the 2 pivotal phase 3 studies, MARINA and ANCHOR. He also noted other, more narrowly focused studies of ranibizumab such as SAILOR, FOCUS, and PrONTO. (*Retinal Physician* has previously reported on

these studies.)

Based on the already completed key studies, Dr. Kaiser concluded that Lucentis has shown itself to be an efficacious drug with an excellent safety profile. He noted that the range of adverse events seen in ranibizumab trials "were really limited to things that we've come to expect with intravitreal injections."

David Brown, MD, provided new information when he announced the 1-year results of the PIER study, which was primarily designed to determine whether ranibizumab could be injected quarterly rather than monthly (after 3 initial monthly injections) and maintain its effectiveness.

Dr. Brown reported that the PIER study showed ranibizumab to be a safe drug. However, while quarterly dosing on average provided a 15- to 16-letter improvement over sham injections, the visual acuity of patients receiving quarterly injections of ranibizumab had on average returned to baseline by month 12.

The PIER data have led Genentech to recommend that patients receive either monthly injections of ranibizumab, or have their retreatment schedules determined through individualized testing.

### **Bevacizumab (Avastin)**

The update on bevacizumab (Avastin, Genentech) was presented by Philip Rosenfeld, MD, PhD, who pioneered the use of bevacizumab as an off-label therapy for the treatment of wet AMD.

Dr. Rosenfeld described how he had initially recognized the molecular similarities between ranibizumab and bevacizumab and determined that bevacizumab might be an effective treatment for wet AMD. He began with intravenous delivery of bevacizumab to a few wet AMD patients.

Dr. Rosenfeld said he was well aware of systemic side effects that occurred with some cancer patients treated with bevacizumab, though he did not see those side effects in his AMD patients. However, he wanted to avoid the potential risk of systemic side effects and switched to intravitreal injection as the delivery method for bevacizumab.

Dr. Rosenfeld reported on a patient who did not respond to photodynamic therapy (PDT), triamcinolone acetonide (Kenalog, Bristol-Myers Squibb), or pegaptanib sodium (Macugen, OSI), but who demonstrated significant and long-lasting visual improvement after just 1 injection of 1.25 mg of bevacizumab.

In terms of safety, he noted that short-term data on 7000 bevacizumab injections raised no major safety concerns.

"No apparent safety signals were identified," he reported.

Dr. Rosenfeld concluded his presentation by saying that retina specialists should not feel guilty about using bevacizumab as a treatment for wet AMD.

"It's legal, and it's ethical if you're using good clinical judgment," he asserted. "Obviously, we do need prospective clinical trials."

### **Other Pharmacotherapies**

Peter Kaiser, MD, discussed several potential but lesser-known wet AMD therapies that are currently in clinical trials — vascular endothelial growth factor (VEGF) Trap (Regeneron), RNA interference (being developed by both Acuity Pharmaceuticals and Sirna Therapeutics), and squalamine (Evizon, Genaera).

Dr. Kaiser finds VEGF Trap particularly interesting because in creating a decoy receptor for VEGF, it binds well to all forms of VEGF and remains effective at low concentrations, possibly offering a longer-lasting duration of action.

Following a promising 6-week, 21-patient phase 1 trial during which the median improvement in visual acuity was 13 letters, Regeneron has initiated a larger phase 2 trial to determine safety and efficacy at doses up to 4 mg.

The mechanism of action of RNA interference is to silence VEGF-producing genes through the injection of a form of double-stranded RNA. Sirna has completed a promising 26-patient, phase 1 trial that consisted of 1 injection. The Sirna compound, which acts against the VEGF receptor, demonstrated improved or stabilized vision in 96% of the study population, with 23% of patients showing a 3 line vision gain at 8 weeks. Sirna is now forming a phase 2 trial.

Acuity has conducted a 15-patient, 2 injection phase 1 trial with its Cand5 compound, which attacks VEGF directly. In this study, 80% of patients demonstrated stable or improved vision. Dr. Kaiser reported that the safety profile of Cand5 proved to be excellent in this trial. A phase 2 trial is currently nearing completion.

Dr. Kaiser briefly mentioned squalamine, an antiangiogenic that is given intravenously and that showed some ability to stabilize vision in phase 2 trials. A new, dose-escalating trial of squalamine has now been initiated.

### **PDT and Intravitreal Steroids**

Albert Augustin, MD, reported on an interesting combination called "triple therapy" in which the patient is treated with an anti-inflammatory steroid, bevacizumab, and modified PDT with a lower light dose.

Dr. Augustin said that in 1 series of 64 eyes, 7 patients who received triple therapy all showed significant improvement in visual acuity in just 1 treatment cycle. A second bevacizumab injection was performed in only 7 eyes.

"We believe this is a more finite treatment," said Dr. Augustin. "It's more a cure vs a suppression of the disease process. Up to now, we haven't seen any steroid-related or other severe side effects of the treatment."

### **The PrONTO Study**

Dr. Rosenfeld had the idea which led to the PrONTO study after treating several patients with ranibizumab who did not require additional retreatment for as long as 31 months. In fact, their vision continued to improve without retreatment. He determined that patients responded differently to this therapy and that retreatment could be determined on an individual basis.

Dr. Rosenfeld reasoned that vision loss was gradual as the fluid accumulated and that optical coherence tomography (OCT) was reliable in detecting the fluid before it became symptomatic. Initially, all patients in the study received 3 monthly injections. They received additional injections only if the OCT measurements showed a need for retreatment.

"Our questions were: how quickly does the OCT improve once we start injecting? How quickly does the visual acuity improve? And can these visual acuity improvements be maintained 2 years if we use this prn regimen?"

The criteria for retreatment as measured by OCT were essentially one or more of the following: loss of at least 5 letters of vision, evidence of fluid, increase in central retinal thickness, new hemorrhage, and/or new evidence of classic choroidal neovascularization (CNV).

Using these criteria, the mean number of injections per patient in year 1 of a 2-year 40-patient study was 5.5, though at least 1 patient received 13 injections. Clearly, the need for re-injection is unpredictable and varies from individual to individual. The PrONTO study offers one way to determine individual retreatment schedules.

### **OCT Assessments of Lucentis**

Dr. Brown reported on quantitative vs qualitative OCT assessments of disease progression following treatment with ranibizumab.

He noted that 4 different types of edema routinely return following treatment with ranibizumab. These are diffuse edema, intraretinal cysts, subretinal edema, and subretinal pigment epithelium fluid.

"A patient has anti-VEGF therapy and gets a nice response," noted Dr. Brown. "With time, after treatment, you get diffuse edema. In other words, there's a thickening but no bubbles. This will only be shown by quantitative OCT if it accurately measures the retinal boundaries."

Dr. Brown reports that in performing quantitative OCT assessments following anti-VEGF treatments, the error rate in identifying the need for retreatment can be as high as 70%. This is because the computer is prone to fixation errors, has difficulty in finding retinal boundaries, and fails to note the presence of subretinal pigment epithelium fluid.

With qualitative OCT assessment, the presence of fluid is visible and easy to detect. When fluid is detected, it is recommended that the retina specialist initiate retreatment.

"As Phil (Rosenfeld) says, he treats when he sees fluid," noted Dr. Brown.

### **High-Resolution SLO/OCT: The Future**

Dr. Rosenfeld reported on the anticipated arrival of "next-generation" OCT technology, which is called spectral domain and is currently being developed by several competing companies, including Carl Zeiss Meditec (Dublin, Calif) and Topcon (Paramus, NJ). Dr. Rosenfeld predicts that one or more of these systems will be commercially available within the next year.

The advantages of spectral domain include increased speed, no moving parts, and 2000 detector elements that generate 29000 lines per second compared to 400 lines per second for today's OCT-3. The result is better sensitivity, higher resolution, and 3-D imaging.

"So, we are going to have higher resolution. It's going to be faster and you are going to be able to reconstruct images. You're going to be able to precisely place where the pathology is in the different layers of the retina based on the vascular landmarks of the fundus image. You are going to be able to do a lot of neat things because you will have this huge database that can be manipulated any way you want," concluded Dr. Rosenfeld.

## **SURGERY**

### **Surgery for AMD: Is It Dead?**

Paul Tornambe, MD, says he never felt that surgery was alive for AMD. Dr. Tornambe says, "Any disease where you treat the effect of the stimulus rather than treating the stimulus is not going to be successful." He says "that until we are able to do something directly with the up-regulation of a VEGF gene, that as long as VEGF keeps getting produced, we're going to have to keep retreating these people." Dr. Tornambe believes that something has to occur further upstream to be effective.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.